Genitourinary Cancers , Softcover reprint of the original 1st ed. 2018 Cancer Treatment and Research Series, Vol. 175

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.

Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University and was then recruited to USC Institute of Urology in 2010 as Director of Urologic Oncology. He is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director. Dr. Daneshmand’s main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following radical cystectomy as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for these diseases in the country. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following orthotopic urinary diversion.  He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy and his protocol has significantly reduced hospital stay while improving the patient experience. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on non-muscle invasive bladde

Provides insights into questions of key importance for the current management of renal, prostate, bladder, and testicular cancers

Covers the full range of management issues with regard to diagnosis, therapy, prognosis, and postoperative care

Takes into account the latest available evidence on all topics